One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end there — up to 30 percent of early-stage breast cancer cases will later ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...

Metastatic breast cancer subtypes and biomarkers are crucial for guiding treatment decisions and managing disease progression. ER-positive, HER2-negative breast cancer treatment often begins with ...